ESU Courses

esu-logo-200

 

 

8 November – 09.00-12.00
Course 1: Daily practice in the management of metastatic prostate cancer
Chair: Steven Joniau, Leuven (BE)

 

09.00 – 09.05      European School of Urology: a unique possibility for urological education
Stevn Joniau, Leuven (BE)

 09.05 – 09.10      Introduction and aims
Steven Joniau, Leuven (BE)

 09.10 – 09.50      Interactive case discussion: The role of imaging and biomarkers in the work-up and risk stratification of metastatic prostate cancer
Gert De Meerleer, Leuven (BE)

 09.50 – 10.30      Interactive case discussion: Optimization of systemic treatment in newly diagnosed hormone-naïve metastatic prostate cancer
Tobias Maurer, Hamburg (DE)

10.30 – 11.00      Interactive case discussion: Treatment of the primary tumor in newly diagnosed hormone-naïve metastatic prostate cancer
Steven Joniau, Leuven (BE)

 11.00 – 11.40      Interactive case discussion: Metastasis-directed treatment in metastatic recurrence following local treatment of prostate cancer
Gert De Meerleer, Leuven (BE)

11.40 – 11.55      ‘New kids on the block’ in the treatment of metastatic prostate cancer
Tobias Maurer, Hamburg (DE)

 11.55 – 12.00      Take home messages and close
Stevn Joniau, Leuven (BE)

 

esu-logo-200

 

 

8 November – 14.00-17.00

Course 2: Immunotherapy for urological tumours
Chair: Jeroen Van Moorselaar, Amsterdam (NL)

 


14.00 – 14.05   European School of Urology: A unique possibility for urological education
Jeroen Van Moorselaar, Amsterdam (NL)

 14.05 – 14.25  Update and current knowledge of immunotherapy in prostate cancer
Laurence Albiges, Villejuif (FR)

 14.25 – 14.55  Immunotherapy for urological tumours: Clinical cases in prostate cancer
Laurence Albiges, Villejuif (FR)

14.55   Break

15.15 – 15.45   Update and current knowledge of immunotherapy in renal cancer
Jeroen Van Moorselaar, Amsterdam (NL)

15.45 – 16.15  Immunotherapy for urological tumours: Clinical cases in renal cancer
Marc-Oliver Grimm, Jena (DE)

16.15 – 16.35    Update and current knowledge of immunotherapy in bladder cancer
Thomas Powles, London (GB)

 16.35 – 16.55   Immunotherapy for urological tumours: Clinical cases in bladder cancer
Thomas Powles, London (GB)

 16.55 – 17.00   Closing remarks
Jeroen Van Moorselaar, Amsterdam (NL)